Hema Now
Jesús San Miguel explores advances in multiple myeloma management, including measurable residual disease, risk stratification, CAR T-cell therapies, and bispecific antibodies, alongside areas of ongoing consensus and future directions in research and treatment.
Spotify | Apple | Amazon Music | YouTube | Download MP3
Jesús San Miguel is Professor of Haematology at the University of Navarra and Consultant Researcher at Cima Universidad de Navarra, Pamplona, Spain. His work focuses on multiple myeloma, measurable residual disease, and new anti-tumour therapies.
Timestamps:
00:00 – Introduction
01:00 – Advances in myeloma management
02:38 – MRD and treatment response
05:21 – Risk stratification in myeloma
07:49 – Areas lacking consensus
10:20 – CAR T and bispecifics
12:45 – Integrating academic haematology
14:44 – Future directions in myeloma
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
Disclosure: Miguel has received payment from Abbvie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Astra Zeneca, Sanofi, SecuraBio and Gilead-Kite, with payment made to the institution.
Keywords: Bispecific antibodies, CAR T-cell therapy, measurable residual disease, multiple myeloma.
